Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China

[1]  Juan Su,et al.  Efficacy and Incidence of Treatment-Related Adverse Events of Thrombopoietin Receptor Agonists in Adults with Immune Thrombocytopenia: A Systematic Review and Network Meta-Analysis of Randomized Controlled Study , 2022, Acta Haematologica.

[2]  D. Kuter.  The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. , 2021, Blood reviews.

[3]  P. Yin,et al.  A multicentre double‐blind, double‐dummy, randomised study of recombinant human thrombopoietin versus eltrombopag in the treatment of immune thrombocytopenia in Chinese adult patients , 2021, British journal of haematology.

[4]  Yahiya Y. Syed.  Hetrombopag: First Approval , 2021, Drugs.

[5]  Jing Liu,et al.  A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia , 2021, Journal of Hematology & Oncology.

[6]  [Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia (version 2020)]. , 2020, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.

[7]  S. Vesely,et al.  American Society of Hematology 2019 guidelines for immune thrombocytopenia. , 2019, Blood advances.

[8]  J. Bussel,et al.  Updated international consensus report on the investigation and management of primary immune thrombocytopenia. , 2019, Blood advances.

[9]  L. F. Allen,et al.  Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia , 2018, British journal of haematology.

[10]  A. Cuker.  Transitioning patients with immune thrombocytopenia to second‐line therapy: Challenges and best practices , 2018, American journal of hematology.

[11]  M. Lambert,et al.  Clinical updates in adult immune thrombocytopenia. , 2017, Blood.

[12]  Jie Jin,et al.  Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia , 2017, British journal of haematology.

[13]  J. Bussel,et al.  A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. , 2014, Blood.

[14]  Ren-chi Yang.  [Thrombosis and hemostasis]. , 2013, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.

[15]  J. George,et al.  Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial , 2008, The Lancet.